Understanding how certain blood cell mutations contribute to heart disease
Official title: Mechanisms of Atherogenesis in Clonal Hematopoiesis
Funded at University of California, San Francisco · NIH-10896311 · Data updated 2026-11-12
This study is looking at how a specific mutation in blood cells, which can happen as we get older, might increase the chances of heart disease and stroke, especially in older adults, and it aims to find ways to help prevent these problems.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $248,981 |
| NIH project number | 5R00HL157649-04 |
| Project ID | NIH-10896311 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults with clonal hematopoiesis, particularly those with the JAK2V617F mutation.
✕Less likely to help
Patients without clonal hematopoiesis or those with other unrelated cardiovascular conditions may not benefit from this research.
What this research studies
This research investigates clonal hematopoiesis (CH), a condition where specific blood cells with mutations proliferate, increasing the risk of heart disease and stroke, particularly in older adults. The study focuses on the JAK2V617F mutation, which is linked to heightened coronary heart disease risk. By using mouse models, researchers will explore how these mutated cells interact with their environment and promote inflammation, potentially leading to heart issues. The research aims to identify mechanisms that could be targeted for therapeutic interventions.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce the risk of heart disease in patients with clonal hematopoiesis.
How similar studies have gone: Previous research has shown that targeting inflammatory pathways in similar conditions can lead to improved outcomes, suggesting potential success for this approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Fidler, Trevor Perawaskin Laramee — University of California, San Francisco
- Study coordinator: Fidler, Trevor Perawaskin Laramee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.